S-222611, a potent, orally active small molecule inhibitor of EGFR and HER2: In vivo antitumor effects

被引：0
|
作者：
Iguchi, Motofumi [1 ]
Tanaka, Hidekazu [1 ]
Wada, Tohru [1 ]
Hojo, Kanji [1 ]
Shinonome, Satomi [1 ]
Sato, Norihito [1 ]
Nezasa, Ken-ichi [1 ]
Orita, Satoshi [1 ]
Abe, Kenji [1 ]
Arimura, Akinori [1 ]
Matsuo, Yoshiyuki [1 ]
Kato, Akira [1 ]
机构：
[1] Shionogi & Co Ltd, Osaka, Japan
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1762
引用
收藏
页数：1
相关论文
共 50 条
  • [1] S-222611, a potent, orally active small molecule inhibitor of EGFR and HER2: in vitro kinase inhibition and antitumor activity
    Hirata, Michinari
    Tanaka, Hidekazu
    Dohi, Keiji
    Iguchi, Motofumi
    Wada, Tohru
    Matsuo, Kenji
    Kume, Masaharu
    Omori, Naoki
    Tada, Yukio
    Orita, Satoshi
    Abe, Kenji
    Arimura, Akinori
    Matsuo, Yoshiyuki
    Kato, Akira
    [J]. CANCER RESEARCH, 2009, 69
  • [2] Antitumor activities of EGFR/HER2/HER4 kinase inhibitor S-222611 in the experimental brain metastases of HER2-positive breast cancer
    Hirata, Michinari
    Tanaka, Yukari
    Shinonome, Satomi
    Yamada, Tomomi
    Torii, Mikinori
    Nezasa, Kenichi
    Tanaka, Hidekazu
    [J]. CANCER RESEARCH, 2017, 77
  • [3] Distribution analysis of S-222611 in brain metastases of HER2-positive breast cancer by quantitative imaging mass spectrometry: prospect for antitumor activity of EGFR/HER2/HER4 kinase inhibitor S-222611 against brain metastases
    Tanaka, Yukari
    Hirata, Michinari
    Shinonome, Satomi
    Matsumoto, Mitsunobu
    Nogami, Wataru
    Torii, Mikinori
    Nezasa, Ken-ichi
    Tanaka, Hidekazu
    [J]. CANCER RESEARCH, 2017, 77
  • [4] A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors
    Baird, Richard D.
    Papa, Sophie
    Cresti, Nicola
    Hatcher, Helen
    Hogarth, Linda
    Jamal-Hanjani, Mariam
    Frenkel, Eugene P.
    Donaldson, Kirsteen
    Posner, John
    Kawabata, Izumi
    Jodrell, Duncan Ian
    Plummer, Ruth
    Spicer, James F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Cresti, N.
    Jodrell, D.
    Arkenau, T.
    Forster, M.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Plummer, R.
    Spicer, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S160 - S161
  • [6] Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.
    Deva, Sanjeev
    Baird, Richard D.
    Cresti, Nicola
    Garcia-Corbacho, Javier
    Hogarth, Linda
    Frenkel, Eugene P.
    Kawaguchi, Keiko
    Arimura, Akinori
    Donaldson, Kirsteen
    Posner, John
    Sarker, Debashis
    Jodrell, Duncan Ian
    Plummer, Ruth
    Spicer, James F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab plus /- chemotherapy in patients with HER2-positive metastatic breast cancer
    Rafii, S.
    Macpherson, I.
    Baird, R.
    Saggese, M.
    Spiliopoulou, P.
    Kumar, S.
    Italiano, A.
    Bonneterre, J.
    Campone, M.
    Cresti, N.
    Posner, J.
    Takeda, Y.
    Arimura, A.
    Spicer, J.
    [J]. CANCER RESEARCH, 2017, 77
  • [8] Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases
    Baird, R. D.
    Arkenau, H-T
    Deva, S.
    Cresti, N.
    Garcia-Corbacho, J.
    Hogarth, L.
    Frenkel, E.
    Kawaguchi, K.
    Arimura, A.
    Donaldson, K.
    Posner, J.
    Sarker, D.
    Jodrell, D.
    Plummer, R.
    Spicer, J.
    Italiano, A.
    [J]. CANCER RESEARCH, 2016, 76
  • [9] Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Spicer, J.
    Baird, R.
    Suder, A.
    Cresti, N.
    Corbacho, J. Garcia
    Hogarth, L.
    Frenkel, E.
    Matsumoto, S.
    Kawabata, I.
    Donaldson, K.
    Posner, J.
    Sarker, D.
    Jodrell, D.
    Plummer, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (02) : 137 - 145
  • [10] Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer
    Baird, R. D.
    Cresti, N.
    Beddowes, E.
    Saggese, M.
    Flynn, M.
    Corbacho, J. Garcia
    Gao, F.
    Lemech, C.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Forster, M.
    Arkenau, H. T.
    Plummer, R.
    Jodrell, D.
    Spicer, J.
    [J]. CANCER RESEARCH, 2013, 73
12345